Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants

Vanderbilt University Medical Center

Status: Completed

Conditions: Lung Cancer

Treatments: Genetic: microarray analysis; Genetic: fluorescence in situ hybridization; Other: laboratory biomarker analysis; Procedure: diagnostic bronchoscopy; Genetic: protein expression analysis; Other: medical chart review; Genetic: comparative genomic hybridization; Genetic: gene expression analysis; Other: immunohistochemistry staining method; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT00899028

R01CA102353 (U.S. NIH Grant/Contract)

CDR0000584223

P30CA068485 (U.S. NIH Grant/Contract)

VU-VICC-THO-0373

VU-VICC-010178

Details and patient eligibility

About

RATIONALE: Studying samples of tissue, blood, sputum, and urine from patients with lung cancer and from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is looking at biomarkers for lung cancer using tissue samples from patients with lung cancer and from healthy participants.

Full description

OBJECTIVES:

• To identify new molecular abnormalities specific to the development of squamous cell carcinoma of the lung.
• To determine the prevalence of candidate biomarkers in lung cancer progression.
• To determine the odds of developing lung cancer according to biomarker status in preinvasive lesions.
• To determine the odds of developing lung cancer according to proteomic biomarker status in the normal bronchial epithelium of high-risk patients.

OUTLINE: This is a multicenter study.

Tissue samples are collected at the time of fluorescence bronchoscopy for laboratory biomarker studies. Blood, sputum, and urine samples are also collected. Gene and protein expression studies are performed on the samples using comparative genomic hybridization array, 3q oligonucleotide microarray, matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF), fluorescence in situ hybridization (FISH), and immunohistochemistry (IHC).

Patients' medical records are reviewed to collect information about the patient's past medical history and pertinent laboratory and radiography results.

Patients and healthy volunteers are followed annually via telephone or a mailed questionnaire.

Enrollment: 689 patients

Sex: All

Ages: 18 to 120 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Meets 1 of the following criteria:

  • Known or previously diagnosed lung cancer

  • Suspected lung cancer, including the following:

    • Completely resected stage I lung cancer (with no evidence of metastatic disease) for which patient is at risk for developing secondary disease
    • Suspected of having lung cancer due to clinical symptoms, such as positive sputum cytology, hemoptysis, unresolved pneumonia, persistent cough, and positive x-ray

  • Healthy volunteer

PATIENT CHARACTERISTICS:

• WBC ≥ 2,000/mm³ but ≤ 20,000/mm³
• Platelet count ≥ 50,000/mm³
• Not pregnant
• No uncontrolled hypertension (i.e., systolic blood pressure > 200 mm Hg, diastolic blood pressure > 120 mm Hg)
• No unstable angina
• No known bleeding disorder
• No other contraindications for white light bronchoscopic examination
• No other contraindications for fluorescence examination

PRIOR CONCURRENT THERAPY:

• More than 3 months since prior fluorescent photosensitizing agents (hematoporphyrin derivatives)
• More than 3 months since prior and no concurrent chemopreventative drugs (e.g., tretinoin)
• More than 6 months since prior ionizing radiation treatment to the chest
• More than 6 months since prior systemic cytotoxic chemotherapy
• No concurrent anticoagulant therapy